ENOV Quote, Financials, Valuation and Earnings

Integra LifeSciences Holdings Corp. has a net margin of -104% compared to Enovis Corp.'s net margin of -1.34%. Enovis Corp.'s return on equity of -52.07% beat Integra LifeSciences Holdings Corp.'s return on equity of -37.15%.

Enovis Corp. has a consensus price target of $47.00, signalling upside risk potential of 78.64%. On the other hand Integra LifeSciences Holdings Corp. has an analysts' consensus of $15.50 which suggests that it could grow by 23.11%. Given that Enovis Corp. has higher upside potential than Integra LifeSciences Holdings Corp., analysts believe Enovis Corp. is more attractive than Integra LifeSciences Holdings Corp..

Enovis Corp. has a beta of 1.284, which suggesting that the stock is 28.371% more volatile than S&P 500. In comparison Integra LifeSciences Holdings Corp. has a beta of 1.064, suggesting its more volatile than the S&P 500 by 6.408%.

Enovis Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Integra LifeSciences Holdings Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Enovis Corp. pays -- of its earnings as a dividend. Integra LifeSciences Holdings Corp. pays out -- of its earnings as a dividend.

Enovis Corp. quarterly revenues are $548.9M, which are larger than Integra LifeSciences Holdings Corp. quarterly revenues of $402.1M. Enovis Corp.'s net income of -$570.9M is lower than Integra LifeSciences Holdings Corp.'s net income of -$5.4M. Notably, Enovis Corp.'s price-to-earnings ratio is -- while Integra LifeSciences Holdings Corp.'s PE ratio is 70.14x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Enovis Corp. is 0.67x versus 0.59x for Integra LifeSciences Holdings Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Merit Medical Systems, Inc. has a net margin of -104% compared to Enovis Corp.'s net margin of 7.22%. Enovis Corp.'s return on equity of -52.07% beat Merit Medical Systems, Inc.'s return on equity of 8.28%.

Enovis Corp. has a consensus price target of $47.00, signalling upside risk potential of 78.64%. On the other hand Merit Medical Systems, Inc. has an analysts' consensus of $103.60 which suggests that it could grow by 18.22%. Given that Enovis Corp. has higher upside potential than Merit Medical Systems, Inc., analysts believe Enovis Corp. is more attractive than Merit Medical Systems, Inc..

Enovis Corp. has a beta of 1.284, which suggesting that the stock is 28.371% more volatile than S&P 500. In comparison Merit Medical Systems, Inc. has a beta of 0.615, suggesting its less volatile than the S&P 500 by 38.504%.

Enovis Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Merit Medical Systems, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Enovis Corp. pays -- of its earnings as a dividend. Merit Medical Systems, Inc. pays out -- of its earnings as a dividend.

Enovis Corp. quarterly revenues are $548.9M, which are larger than Merit Medical Systems, Inc. quarterly revenues of $384.3M. Enovis Corp.'s net income of -$570.9M is lower than Merit Medical Systems, Inc.'s net income of $27.8M. Notably, Enovis Corp.'s price-to-earnings ratio is -- while Merit Medical Systems, Inc.'s PE ratio is 44.85x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Enovis Corp. is 0.67x versus 3.60x for Merit Medical Systems, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Repligen Corp. has a net margin of -104% compared to Enovis Corp.'s net margin of 7.9%. Enovis Corp.'s return on equity of -52.07% beat Repligen Corp.'s return on equity of 0.09%.

Enovis Corp. has a consensus price target of $47.00, signalling upside risk potential of 78.64%. On the other hand Repligen Corp. has an analysts' consensus of $189.22 which suggests that it could grow by 13.74%. Given that Enovis Corp. has higher upside potential than Repligen Corp., analysts believe Enovis Corp. is more attractive than Repligen Corp..

Enovis Corp. has a beta of 1.284, which suggesting that the stock is 28.371% more volatile than S&P 500. In comparison Repligen Corp. has a beta of 1.110, suggesting its more volatile than the S&P 500 by 11.028%.

Enovis Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Repligen Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Enovis Corp. pays -- of its earnings as a dividend. Repligen Corp. pays out -- of its earnings as a dividend.

Enovis Corp. quarterly revenues are $548.9M, which are larger than Repligen Corp. quarterly revenues of $188.8M. Enovis Corp.'s net income of -$570.9M is lower than Repligen Corp.'s net income of $14.9M. Notably, Enovis Corp.'s price-to-earnings ratio is -- while Repligen Corp.'s PE ratio is 6,448.06x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Enovis Corp. is 0.67x versus 13.26x for Repligen Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Twist Bioscience Corp. has a net margin of -104% compared to Enovis Corp.'s net margin of -27.41%. Enovis Corp.'s return on equity of -52.07% beat Twist Bioscience Corp.'s return on equity of -16.74%.

Enovis Corp. has a consensus price target of $47.00, signalling upside risk potential of 78.64%. On the other hand Twist Bioscience Corp. has an analysts' consensus of $35.88 which suggests that it could grow by 6.01%. Given that Enovis Corp. has higher upside potential than Twist Bioscience Corp., analysts believe Enovis Corp. is more attractive than Twist Bioscience Corp..

Enovis Corp. has a beta of 1.284, which suggesting that the stock is 28.371% more volatile than S&P 500. In comparison Twist Bioscience Corp. has a beta of 2.242, suggesting its more volatile than the S&P 500 by 124.157%.

Enovis Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Twist Bioscience Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Enovis Corp. pays -- of its earnings as a dividend. Twist Bioscience Corp. pays out -- of its earnings as a dividend.

Enovis Corp. quarterly revenues are $548.9M, which are larger than Twist Bioscience Corp. quarterly revenues of $99M. Enovis Corp.'s net income of -$570.9M is lower than Twist Bioscience Corp.'s net income of -$27.1M. Notably, Enovis Corp.'s price-to-earnings ratio is -- while Twist Bioscience Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Enovis Corp. is 0.67x versus 5.40x for Twist Bioscience Corp.. Usually stocks with elevated PS ratios are considered overvalued.